Updated NETs Clinical Trials

Studies found on ClinicalTrials.gov by a search of: neuroendocrine NOT Melanoma NOT PMS | Recruiting, Not yet recruiting, Available Studies | Phase 2, 3, 4 | Last update posted in the last 30 days

  1. A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer

    Conditions:   Metastatic Prostate Neuroendocrine Carcinoma;   Metastatic Prostate Cancer
    Interventions:   Drug: Nivolumab;   Drug: Ipilimumab;   Drug: Carboplatin;   Drug: Cabazitaxel
    Sponsors:   Andrew J. Armstrong, MD;   Bristol-Myers Squibb
    Recruiting

  2. Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

    Conditions:   VHL Pancreatic Neuroendocrine Tumors;   Von Hippel-Lindau Disease;   Neuroendocrine Tumors
    Intervention:   Drug: 68-Gallium DOTATATE
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  3. Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Metastatic Small Cell Neuroendocrine Carcinomas That Originate Outside the Lung

    Conditions:   Extrapulmonary Small Cell Neuroendocrine Carcinoma;   Recurrent Extrapulmonary Small Cell Neuroendocrine Carcinoma;   Recurrent Small Cell Neuroendocrine Carcinoma;   Small Cell Neuroendocrine Carcinoma
    Interventions:   Biological: Atezolizumab;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Other: Patient Observation
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  4. Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET

    Conditions:   Small-cell Lung Cancer;   Neuroendocrine Carcinoma
    Interventions:   Drug: Iadademstat;   Drug: Paclitaxel
    Sponsor:   Fox Chase Cancer Center
    Not yet recruiting

  5. Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

    Conditions:   EGFR-Mutated Non-Small-Cell Lung Carcinoma;   Small Cell/Neuroendocrine
    Interventions:   Drug: Olaparib;   Drug: Durvalumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  6. Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), or Von Hippel-Lindau (VHL) Disease-Associated Tumors (MK-6482-015)

    Conditions:   Pheochromocytoma/Paraganglioma;   Pancreatic Neuroendocrine Tumor;   Von Hippel-Lindau Disease
    Intervention:   Drug: Belzutifan
    Sponsor:   Merck Sharp & Dohme LLC
    Recruiting

  7. Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin

    Conditions:   Locally Advanced Digestive System Neuroendocrine Carcinoma;   Locally Advanced Pancreatic Neuroendocrine Carcinoma;   Metastatic Digestive System Neuroendocrine Carcinoma;   Metastatic Pancreatic Neuroendocrine Carcinoma;   Refractory Digestive System Neuroendocrine Carcinoma;   Refractory Pancreatic Neuroendocrine Carcinoma;   Unresectable Digestive System Neuroendocrine Carcinoma;   Unresectable Pancreatic Neuroendocrine Carcinoma
    Interventions:   Drug: Fluorouracil;   Drug: Leucovorin;   Drug: Liposomal Irinotecan;   Procedure: Quality-of-Life Assessment
    Sponsors:   Roswell Park Cancer Institute;   Ipsen
    Recruiting

  8. Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

    Conditions:   Atypical Carcinoid Tumor;   Carcinoid Tumor;   Functioning Pancreatic Neuroendocrine Tumor;   Intermediate Grade Lung Neuroendocrine Neoplasm;   Locally Advanced Pancreatic Neuroendocrine Tumor;   Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm;   Low Grade Lung Neuroendocrine Neoplasm;   Lung Atypical Carcinoid Tumor;   Lung Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Neoplasm;   Metastatic Digestive System Neuroendocrine Tumor G1;   Metastatic Pancreatic Neuroendocrine Tumor;   Metastatic Thymic Neuroendocrine Neoplasm;   Neuroendocrine Neoplasm;   Non-Functioning Pancreatic Neuroendocrine Tumor;   Pancreatic Serotonin-Producing Neuroendocrine Tumor;   Stage IIIA Digestive System Neuroendocrine Tumor AJCC v7;   Stage IIIB Digestive System Neuroendocrine Tumor AJCC v7;   Stage IV Digestive System Neuroendocrine Tumor AJCC v7
    Interventions:   Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Placebo Administration;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  9. Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor

    Conditions:   Locally Advanced Neuroendocrine Neoplasm;   Metastatic Neuroendocrine Neoplasm
    Interventions:   Drug: Placebo Administration;   Other: Questionnaire Administration;   Drug: Telotristat Ethyl
    Sponsors:   M.D. Anderson Cancer Center;   TerSera Therapeutics LLC
    Recruiting

  10. Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

    Conditions:   Gastroenteropancreatico Tumors;   Neuroendocrine Tumors;   Neuroendocrine Neoplasms
    Interventions:   Drug: Lu-177-DOTATATE;   Drug: Olaparib;   Diagnostic Test: Ga dotatate scanning;   Diagnostic Test: FDG-PET scanning
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting

  11. Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers

    Conditions:   SCLC;   Small Cell Cancer;   Advanced Solid Tumor;   High Grade Neuroendocrine Cancers
    Interventions:   Drug: Lurbinectedin;   Drug: Berzosertib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  12. Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

    Conditions:   Gastroenteropancreatic Neuroendocrine Tumors;   Pheochromocytoma;   Paraganglioma
    Intervention:   Drug: Lutetium [177Lu] oxodotreotide/dotatate
    Sponsor:   Advanced Accelerator Applications
    Recruiting

  13. Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer

    Conditions:   Advanced Adrenal Gland Pheochromocytoma;   Advanced Paraganglioma;   Metastatic Adrenal Gland Pheochromocytoma;   Metastatic Paraganglioma;   Unresectable Adrenal Gland Pheochromocytoma;   Unresectable Paraganglioma
    Interventions:   Drug: Olaparib;   Other: Quality-of-Life Assessment;   Drug: Temozolomide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  14. Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors

    Conditions:   Advanced Solid Tumor;   Metastatic Solid Tumor;   Urothelial Carcinoma;   Large Cell Neuroendocrine Carcinoma of the Lung;   Homologous Recombination Deficiency
    Intervention:   Drug: Lurbinectedin
    Sponsor:   Jazz Pharmaceuticals
    Recruiting

  15. Hormone Secretion in Transgender Males

    Conditions:   Transgender;   Healthy
    Interventions:   Drug: Testosterone Cyp 200Mg/Ml Inj (in Oil);   Drug: Letrozole
    Sponsor:   University of California, San Diego
    Not yet recruiting

  16. A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors

    Conditions:   Locally Advanced Solid Tumor;   Metastatic Solid Tumor
    Intervention:   Drug: JBI-802
    Sponsor:   Jubilant Therapeutics Inc.
    Recruiting

  17. Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

    Conditions:   Pheochromocytoma;   Paraganglioma;   Neuroendocrine Tumors;   Neuroendocrine Neoplasms
    Interventions:   Drug: Lu-177-DOTATATE;   Drug: Ga-68-DOTATATE;   Drug: F-18-FDG;   Drug: Amino Acid solution
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  18. Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

    Conditions:   Bile Duct Cancer;   Gall Bladder Cancer;   Breast Cancer;   Neuroendocrine Tumors;   Ovarian Cancer;   Pancreatic Adenocarcinoma;   Soft Tissue Sarcoma;   Vulvar Cancer;   Prostate Cancer
    Interventions:   Drug: Atezolizumab;   Drug: Tivozanib
    Sponsors:   University of Florida;   Genentech, Inc.;   Aveo Oncology Pharmaceuticals
    Recruiting

  19. The IPLA-OVCA Trial, Intra-Peritoneal Local Anaesthetics in Ovarian Cancer

    Condition:   Advanced Ovarian Cancer
    Interventions:   Drug: Ropivacaine;   Drug: Saline Solution
    Sponsors:   Karolinska Institutet;   Skane University Hospital
    Recruiting

  20. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    Conditions:   Bladder Adenocarcinoma;   Bladder Clear Cell Adenocarcinoma;   Bladder Mixed Adenocarcinoma;   Bladder Neuroendocrine Carcinoma;   Bladder Small Cell Neuroendocrine Carcinoma;   Bladder Squamous Cell Carcinoma;   Bladder Urachal Adenocarcinoma;   Chromophobe Renal Cell Carcinoma;   Collecting Duct Carcinoma;   Infiltrating Bladder Lymphoepithelioma-Like Carcinoma;   Infiltrating Bladder Urothelial Carcinoma;   Infiltrating Bladder Urothelial Carcinoma With Giant Cells;   Infiltrating Bladder Urothelial Carcinoma, Nested Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Kidney Medullary Carcinoma;   Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Carcinoma;   Metastatic Bladder Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Small Cell Neuroendocrine Carcinoma;   Metastatic Bladder Squamous Cell Carcinoma;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Metastatic Kidney Medullary Carcinoma;   Metastatic Malignant Genitourinary System Neoplasm;   Metastatic Penile Carcinoma;   Metastatic Prostate Small Cell Neuroendocrine Carcinoma;   Metastatic Sarcomatoid Renal Cell Carcinoma;   Metastatic Urethral Carcinoma;   Papillary Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Stage IV Urethral Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   Testicular Leydig Cell Tumor;   Testicular Sertoli Cell Tumor;   Urethral Clear Cell Adenocarcinoma
    Interventions:   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  21. Non-Viral TCR Gene Therapy

    Conditions:   Endocrine/Neuroendocrine;   Non-Small Cell Lung Cancer;   Breast Cancer;   Gastrointestinal/Genitourinary Cancers;   Ovarian Cancer
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Aldesleukin;   Biological: Sleeping Beauty Transposed PBL
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  22. The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer

    Condition:   Metastic Thyroid Cancer
    Intervention:   Drug: 68-Gallium-DOTATATE-PET/CT
    Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting

  23. Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

    Conditions:   Endocrine Tumors;   Non-Small Cell Lung Cancer;   Ovarian Cancer;   Breast Cancer;   Gastrointestinal/Genitourinary Cancers;   Neuroendocrine Tumors;   Multiple Myeloma
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin;   Biological: Individual Patient TCR-Transduced PBL;   Drug: Pembrolizumab (KEYTRUDA )
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  24. A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

    Condition:   Medullary Thyroid Cancer
    Interventions:   Drug: Selpercatinib;   Drug: Cabozantinib;   Drug: Vandetanib
    Sponsors:   Loxo Oncology, Inc.;   Eli Lilly and Company
    Recruiting

  25. Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

    Conditions:   Advanced Cancer;   Anal Carcinoma;   Anal Cancer;   Biliary Cancer;   Cholangiocarcinoma;   Bile Duct Cancer;   Neuroendocrine Tumor;   Carcinoid Tumor;   Endometrial Carcinoma;   Endometrial Cancer;   Cervical Carcinoma;   Cervical Cancer;   Vulvar Carcinoma;   Vulvar Cancer;   Small Cell Lung Carcinoma;   Small Cell Lung Cancer (SCLC);   Mesothelioma;   Thyroid Carcinoma;   Thyroid Cancer;   Salivary Gland Carcinoma;   Salivary Gland Cancer;   Salivary Cancer;   Parotid Gland Cancer;   Advanced Solid Tumors;   Colorectal Carcinoma
    Intervention:   Biological: pembrolizumab
    Sponsor:   Merck Sharp & Dohme LLC
    Recruiting

  26. A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

    Conditions:   Locally Advanced Solid Tumors;   Metastatic Solid Tumors
    Intervention:   Drug: Oral repotrectinib (TPX-0005)
    Sponsors:   Turning Point Therapeutics, Inc.;   Zai Lab (Shanghai) Co., Ltd.
    Recruiting

  27. Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

    Conditions:   Atypical Teratoid/Rhabdoid Tumor;   Epithelioid Sarcoma;   Kidney Medullary Carcinoma;   Malignant Solid Neoplasm;   Poorly Differentiated Chordoma;   Recurrent Atypical Teratoid/Rhabdoid Tumor;   Recurrent Chordoma;   Recurrent Epithelioid Sarcoma;   Recurrent Kidney Medullary Carcinoma;   Recurrent Rhabdoid Tumor;   Refractory Atypical Teratoid/Rhabdoid Tumor;   Refractory Chordoma;   Refractory Epithelioid Sarcoma;   Refractory Kidney Medullary Carcinoma;   Refractory Rhabdoid Tumor;   Rhabdoid Tumor
    Interventions:   Biological: Atezolizumab;   Biological: Tiragolumab
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting

  28. A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

    Conditions:   Non-Small Cell Lung Cancer;   Medullary Thyroid Cancer;   Colon Cancer;   Any Solid Tumor
    Intervention:   Drug: LOXO-292
    Sponsors:   Loxo Oncology, Inc.;   Eli Lilly and Company
    Recruiting

  29. L19IL2/L19TNF in Skin Cancer Patients

    Conditions:   BCC - Basal Cell Carcinoma;   SCC - Squamous Cell Carcinoma;   Merkel Cell Carcinoma;   Keratoacanthoma of Skin;   Malignant Adnexal Tumors of the Skin (MATS);   Tumors From Cutaneous T-cell Lymphoma (CTCL);   Kaposi Sarcoma
    Intervention:   Drug: L19IL2/L19TNF
    Sponsor:   Philogen S.p.A.
    Not yet recruiting

  30. CMP-001 in Combination With IV PD-1-Blocking Antibody in Subjects With Certain Types of Advanced or Metastatic Cancer

    Conditions:   Merkel Cell Carcinoma;   Cutaneous Squamous Cell Carcinoma;   Metastatic Cancer;   Triple Negative Breast Cancer;   Advanced Cancer
    Interventions:   Drug: CMP-001;   Drug: cemiplimab-rwlc
    Sponsors:   Checkmate Pharmaceuticals;   Regeneron Pharmaceuticals
    Recruiting

  31. Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, the RadiCaL Study

    Conditions:   Advanced Renal Cell Carcinoma;   Chromophobe Renal Cell Carcinoma;   Clear Cell Renal Cell Carcinoma;   Collecting Duct Carcinoma;   Kidney Medullary Carcinoma;   Metastatic Malignant Neoplasm in the Bone;   Papillary Renal Cell Carcinoma;   Stage IV Renal Cell Cancer AJCC v8;   Unclassified Renal Cell Carcinoma
    Interventions:   Drug: Cabozantinib S-malate;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radium Ra 223 Dichloride
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  32. Adjuvant Avelumab in Merkel Cell Cancer

    Conditions:   Stage III Merkel Cell Carcinoma AJCC v8;   Stage IIIB Merkel Cell Carcinoma AJCC v8;   Stage IIIA Merkel Cell Carcinoma AJCC v8
    Interventions:   Drug: Avelumab;   Other: Peripheral Blood Collection;   Other: Placebo
    Sponsors:   University of Washington;   EMD Serono
    Recruiting

  33. Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

    Conditions:   Adenoid Cystic Skin Carcinoma;   Adnexal Carcinoma;   Anaplastic Large Cell Lymphoma, ALK-Negative;   Anaplastic Large Cell Lymphoma, ALK-Positive;   Apocrine Carcinoma;   Cylindrocarcinoma;   Digital Papillary Adenocarcinoma;   Endocrine Mucin-Producing Sweat Gland Carcinoma;   Extramammary Paget Disease;   Extraocular Cutaneous Sebaceous Carcinoma;   Hidradenocarcinoma;   Keratoacanthoma;   Malignant Sweat Gland Neoplasm;   Merkel Cell Carcinoma;   Microcystic Adnexal Carcinoma;   NK-Cell Lymphoma, Unclassifiable;   Papillary Adenocarcinoma;   Porocarcinoma;   Primary Cutaneous Mucinous Carcinoma;   Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Recurrent T-Cell Non-Hodgkin Lymphoma;   Refractory Anaplastic Large Cell Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Refractory Merkel Cell Carcinoma;   Refractory Mycosis Fungoides;   Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Skin Squamous Cell Carcinoma;   Refractory T-Cell Non-Hodgkin Lymphoma;   Sezary Syndrome;   Signet Ring Cell Carcinoma;   Skin Basal Cell Carcinoma;   Skin Basosquamous Cell Carcinoma;   Skin Squamous Cell Carcinoma;   Spiradenocarcinoma;   Squamoid Eccrine Ductal Carcinoma;   Squamous Cell Carcinoma of Unknown Primary;   Sweat Gland Carcinoma;   Trichilemmal Carcinoma;   Vulvar Squamous Cell Carcinoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Biological: Talimogene Laherparepvec
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  34. Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients >= 18 Years Old With Advanced Stage Rare Cancers, RARE 2 Study

    Conditions:   Adrenal Gland Pheochromocytoma;   Hematopoietic and Lymphoid Cell Neoplasm;   Malignant Solid Neoplasm;   Paraganglioma
    Interventions:   Drug: Talazoparib;   Drug: Temozolomide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  35. Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas

    Condition:   Neurofibromatosis Type 2
    Interventions:   Drug: REC-2282;   Drug: Placebo
    Sponsor:   Recursion Pharmaceuticals Inc.
    Recruiting

  36. Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma

    Condition:   Merkel Cell Carcinoma
    Interventions:   Drug: KRT-232;   Drug: Avelumab
    Sponsor:   Kartos Therapeutics, Inc.
    Recruiting

  37. Innovative Trial for Understanding the Impact of Targeted Therapies in NF2

    Conditions:   Neurofibromatosis Type 2;   Vestibular Schwannoma;   Non-vestibular Schwannoma;   Meningioma;   Ependymoma
    Intervention:   Drug: Brigatinib
    Sponsors:   Scott R. Plotkin, MD, PhD;   Takeda;   The Children's Tumor Foundation
    Recruiting

  38. Study of Aspirin in Patients With Vestibular Schwannoma

    Conditions:   Vestibular Schwannoma;   Acoustic Neuroma;   Neurofibromatosis 2
    Interventions:   Drug: Aspirin;   Drug: Placebo
    Sponsors:   Massachusetts Eye and Ear Infirmary;   United States Department of Defense;   Massachusetts General Hospital
    Recruiting

  39. A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

    Conditions:   Central Nervous System Nongerminomatous Germ Cell Tumor;   Choriocarcinoma;   Embryonal Carcinoma;   Immature Teratoma;   Malignant Teratoma;   Mixed Germ Cell Tumor;   Pineal Region Germ Cell Tumor;   Pineal Region Immature Teratoma;   Pineal Region Yolk Sac Tumor;   Suprasellar Germ Cell Tumor
    Interventions:   Drug: Carboplatin;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Ifosfamide;   Drug: Mesna;   Biological: Pegfilgrastim;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Procedure: Second-Look Surgery;   Drug: Thiotepa
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting